20 results on '"Wei, Andrew"'
Search Results
2. Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts
3. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
4. Domestic lending and the pandemic: How does banks’ exposure to COVID-19 abroad affect their lending in the United States?
5. Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes
6. Venetoclax–based low intensity therapy in molecular failure of NPM1-mutated AML
7. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
8. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML).
9. Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (m IDH1 ) acute myeloid leukemia (AML)
10. Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC)
11. Single-cell Rapid Capture Hybridization sequencing (scRaCH-seq) to reliably detect isoform usage and coding mutations in targeted genes at a single-cell level
12. Corporate tax policy, Shariah compliance and financial decisions: evidence from Malaysia
13. 2007 – INFORMING THERAPEUTIC APPROACHES FOR P53 DEFECTIVE BLOOD CANCERS
14. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML‐001.
15. Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy
16. CD34‐TdT‐B‐ALL masquerading as Burkitt lymphoma.
17. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
18. Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3 .
19. How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
20. Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.